Navigation Links
U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVie's Humira, as a Result of Its Recent Approval in Ulcerative Colitis
Date:11/14/2013

BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and third-lines, for newly diagnosed ulcerative colitis (UC) patients.

The report entitled Key Findings from Treatment Algorithms in Ulcerative Colitis finds that Janssen's Remicade is the most prescribed biologic for recently treated UC patients, followed by AbbVie's Humira. Patient share for Humira has grown 41 percent over the past year under study, likely due to its FDA approval for use in UC in September 2012. Overall, the use of TNF-alpha inhibitors has increased by 17 percent since 2012.

The findings also reveal that Remicade is more often used as a first-line biologic and therefore had more continuing patients than Humira. However, since Humira is typically used as a later-line biologic, it draws more patients from adding/switching.

"Both Remicade and Humira have very high compliance and persistency rates, which is likely adding to the increased prescriptions," said Decision Resources Analyst Jen Dolga. "However, it is important to note that despite the growth in biologic use, oral aminosalicylates remain the most commonly prescribed drug class for both newly diagnosed and recently treated patients, indicating that a less intimidating side effect profile is still important to gastroenterologists."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
2. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
6. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
7. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
8. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
9. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
10. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
11. DePuy Settlement Funding And Transvaginal Mesh Capital Increased At Legal-Bay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):